The company has ditched a trial of drebuxelimab plus ivonescimab.
ApexOnco Front Page
Recent articles
CRB-601 and PF-06940434 fall by the wayside.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
